interferon induced protein with tetratricopeptide repeats 1Genealiases: C56 · G10P1 · IFI-56 · IFI-56K · IFI56 · IFIT-1
Q-omics provides the consensus-scored IFIT1 profile across patient tissues and cancer cell-line models. IFIT1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IFIT1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, IFIT1 RNA expression shows 17,000 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where IFIT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFIT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFIT1 survival associations across molecular data types. IFIT1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFIT1 RNA expression–survival associations across cancer types. High IFIT1 expression shows unfavorable associations in HNSC and UVM, but favorable associations in KIRC, KIRP, SKCM and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IFIT1 RNA expression.
This table summarizes IFIT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IFIT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFIT1 shows lower tumor expression in KICH, KIRP, LUSC, COAD and UCEC and higher tumor expression in HNSC. The HNSC box plot shows higher IFIT1 RNA expression in tumor versus normal tissue (log2 FC = +3.729, t-test p < 0.001).
This table shows molecular features associated with IFIT1 in patient tissues and cancer cell lines. In patient samples, IFIT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFIT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
